[BARKLEY PMHNP EXAM] – QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED ANSWERS | PLUS
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Foundational Theories and Psychotherapy
2. Neurobiology and Psychopharmacology
3. Diagnostic Criteria and Assessment (DSM-5-TR)
4. Psychiatric Evaluation and Patient Interviewing
5. Treatment Modalities and Interventions
6. Ethics, Legal Issues, and Professional Standards
7. Regulatory Compliance and Healthcare Policy
8. Cultural Competency and Health Disparities
9. Advanced Practice Nursing Roles and Interprofessional Collaboration
10. Quality Improvement and Evidence-Based Practice
Introduction
This comprehensive assessment is meticulously designed to evaluate the advanced knowledge, clinical reasoning, and
decision-making skills essential for the Psychiatric-Mental Health Nurse Practitioner (PMHNP). The exam covers a
broad spectrum of foundational theory, neurobiological principles, diagnostic criteria, and evidence-based treatment
modalities. Through a rigorous combination of multiple-choice questions and complex clinical scenarios, candidates will
be challenged to apply their understanding to real-world situations, integrating ethical, legal, and regulatory standards.
This assessment emphasizes the critical thinking required for autonomous practice, ensuring that the PMHNP is
prepared to provide safe, patient-centered, and culturally competent care across diverse clinical settings.
,SECTION ONE: QUESTIONS 1–100
1. A patient with Major Depressive Disorder has been on fluoxetine 20 mg daily for 8 weeks with minimal
response. The PMHNP decides to augment the treatment. Which of the following is a first-line augmentation
strategy according to the STAR*D trial?
A. Lithium
B. Buspirone
C. Aripiprazole
D. Bupropion SR
🟢 C. Aripiprazole
🔴 Explanation: The STAR*D trial demonstrated that augmentation with the atypical antipsychotic aripiprazole was
an effective and first-line strategy for patients with inadequate response to SSRIs. While bupropion and buspirone
are also used, aripiprazole has robust evidence for this indication.
2. In differentiating between Bipolar I and Bipolar II disorders, which of the following is the most critical
diagnostic factor?
A. The severity of depressive episodes
B. The presence of psychotic features
C. The history of a full manic episode
D. The frequency of mood episodes
🟢 C. The history of a full manic episode
🔴 Explanation: The presence of at least one full manic episode defines Bipolar I disorder. Bipolar II disorder is
characterized by hypomanic episodes and major depressive episodes, without a history of mania. The key
differentiating factor is the presence and severity of the manic episode.
,3. A 72-year-old patient with Parkinson’s disease presents with visual hallucinations and paranoid delusions.
Which of the following antipsychotic medications is considered the safest first-line agent in this population?
A. Haloperidol
B. Olanzapine
C. Quetiapine
D. Pimavanserin
🟢 D. Pimavanserin
🔴 Explanation: Pimavanserin is a selective 5-HT2A inverse agonist approved specifically for hallucinations and
delusions associated with Parkinson’s disease psychosis. It has a favorable side-effect profile and does not worsen
motor symptoms, unlike typical or many atypical antipsychotics.
4. According to the DSM-5-TR, which of the following is required for a diagnosis of Generalized Anxiety Disorder
(GAD)?
A. Excessive worry occurring more days than not for at least 3 months
B. Panic attacks are a core feature
C. Worry is difficult to control and is associated with at least three physical symptoms
D. Symptoms must be present for at least 6 months
🟢 C. Worry is difficult to control and is associated with at least three physical symptoms
🔴 Explanation: For GAD, the excessive worry must be difficult to control and be associated with at least three of six
physical symptoms (e.g., restlessness, fatigue, muscle tension). The duration of symptoms must be at least 6 months,
not 3 months, making option D incorrect.
5. A 25-year-old female patient with a history of bulimia nervosa is prescribed fluoxetine. What is the primary
therapeutic mechanism of fluoxetine in this disorder?
, A. Blocking dopamine D2 receptors to reduce reward-seeking behavior
B. Reducing obsessive-compulsive and binge-eating behaviors by increasing serotonin
C. Acting as a norepinephrine reuptake inhibitor to decrease appetite
D. Antagonizing histamine H1 receptors to induce sedation and reduce anxiety
🟢 B. Reducing obsessive-compulsive and binge-eating behaviors by increasing serotonin
🔴 Explanation: Fluoxetine, an SSRI, is FDA-approved for bulimia nervosa. Its primary mechanism in this context is
thought to be the reduction of impulsive and binge-purge behaviors through its effects on the serotonergic system,
which modulates impulse control and satiety.
6. A PMHNP is evaluating a patient who reports taking St. John’s Wort for depression. The patient is also
prescribed warfarin. What is the primary risk of this combination?
A. Increased risk of serotonin syndrome
B. Increased risk of bleeding
C. Reduced efficacy of St. John's Wort
D. Increased risk of hepatotoxicity
🟢 B. Increased risk of bleeding
🔴 Explanation: St. John's Wort induces the CYP3A4 and CYP2C9 enzymes, which can lead to decreased efficacy of
warfarin, but more critically, it can also have additive anticoagulant effects, increasing the risk of bleeding when
combined with warfarin.
7. Which of the following best describes the mechanism of action of aripiprazole?
A. Full D2 antagonism and 5-HT2A antagonism
B. Partial D2 agonism and 5-HT2A antagonism
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Foundational Theories and Psychotherapy
2. Neurobiology and Psychopharmacology
3. Diagnostic Criteria and Assessment (DSM-5-TR)
4. Psychiatric Evaluation and Patient Interviewing
5. Treatment Modalities and Interventions
6. Ethics, Legal Issues, and Professional Standards
7. Regulatory Compliance and Healthcare Policy
8. Cultural Competency and Health Disparities
9. Advanced Practice Nursing Roles and Interprofessional Collaboration
10. Quality Improvement and Evidence-Based Practice
Introduction
This comprehensive assessment is meticulously designed to evaluate the advanced knowledge, clinical reasoning, and
decision-making skills essential for the Psychiatric-Mental Health Nurse Practitioner (PMHNP). The exam covers a
broad spectrum of foundational theory, neurobiological principles, diagnostic criteria, and evidence-based treatment
modalities. Through a rigorous combination of multiple-choice questions and complex clinical scenarios, candidates will
be challenged to apply their understanding to real-world situations, integrating ethical, legal, and regulatory standards.
This assessment emphasizes the critical thinking required for autonomous practice, ensuring that the PMHNP is
prepared to provide safe, patient-centered, and culturally competent care across diverse clinical settings.
,SECTION ONE: QUESTIONS 1–100
1. A patient with Major Depressive Disorder has been on fluoxetine 20 mg daily for 8 weeks with minimal
response. The PMHNP decides to augment the treatment. Which of the following is a first-line augmentation
strategy according to the STAR*D trial?
A. Lithium
B. Buspirone
C. Aripiprazole
D. Bupropion SR
🟢 C. Aripiprazole
🔴 Explanation: The STAR*D trial demonstrated that augmentation with the atypical antipsychotic aripiprazole was
an effective and first-line strategy for patients with inadequate response to SSRIs. While bupropion and buspirone
are also used, aripiprazole has robust evidence for this indication.
2. In differentiating between Bipolar I and Bipolar II disorders, which of the following is the most critical
diagnostic factor?
A. The severity of depressive episodes
B. The presence of psychotic features
C. The history of a full manic episode
D. The frequency of mood episodes
🟢 C. The history of a full manic episode
🔴 Explanation: The presence of at least one full manic episode defines Bipolar I disorder. Bipolar II disorder is
characterized by hypomanic episodes and major depressive episodes, without a history of mania. The key
differentiating factor is the presence and severity of the manic episode.
,3. A 72-year-old patient with Parkinson’s disease presents with visual hallucinations and paranoid delusions.
Which of the following antipsychotic medications is considered the safest first-line agent in this population?
A. Haloperidol
B. Olanzapine
C. Quetiapine
D. Pimavanserin
🟢 D. Pimavanserin
🔴 Explanation: Pimavanserin is a selective 5-HT2A inverse agonist approved specifically for hallucinations and
delusions associated with Parkinson’s disease psychosis. It has a favorable side-effect profile and does not worsen
motor symptoms, unlike typical or many atypical antipsychotics.
4. According to the DSM-5-TR, which of the following is required for a diagnosis of Generalized Anxiety Disorder
(GAD)?
A. Excessive worry occurring more days than not for at least 3 months
B. Panic attacks are a core feature
C. Worry is difficult to control and is associated with at least three physical symptoms
D. Symptoms must be present for at least 6 months
🟢 C. Worry is difficult to control and is associated with at least three physical symptoms
🔴 Explanation: For GAD, the excessive worry must be difficult to control and be associated with at least three of six
physical symptoms (e.g., restlessness, fatigue, muscle tension). The duration of symptoms must be at least 6 months,
not 3 months, making option D incorrect.
5. A 25-year-old female patient with a history of bulimia nervosa is prescribed fluoxetine. What is the primary
therapeutic mechanism of fluoxetine in this disorder?
, A. Blocking dopamine D2 receptors to reduce reward-seeking behavior
B. Reducing obsessive-compulsive and binge-eating behaviors by increasing serotonin
C. Acting as a norepinephrine reuptake inhibitor to decrease appetite
D. Antagonizing histamine H1 receptors to induce sedation and reduce anxiety
🟢 B. Reducing obsessive-compulsive and binge-eating behaviors by increasing serotonin
🔴 Explanation: Fluoxetine, an SSRI, is FDA-approved for bulimia nervosa. Its primary mechanism in this context is
thought to be the reduction of impulsive and binge-purge behaviors through its effects on the serotonergic system,
which modulates impulse control and satiety.
6. A PMHNP is evaluating a patient who reports taking St. John’s Wort for depression. The patient is also
prescribed warfarin. What is the primary risk of this combination?
A. Increased risk of serotonin syndrome
B. Increased risk of bleeding
C. Reduced efficacy of St. John's Wort
D. Increased risk of hepatotoxicity
🟢 B. Increased risk of bleeding
🔴 Explanation: St. John's Wort induces the CYP3A4 and CYP2C9 enzymes, which can lead to decreased efficacy of
warfarin, but more critically, it can also have additive anticoagulant effects, increasing the risk of bleeding when
combined with warfarin.
7. Which of the following best describes the mechanism of action of aripiprazole?
A. Full D2 antagonism and 5-HT2A antagonism
B. Partial D2 agonism and 5-HT2A antagonism
